Genentech pulls Raptiva over PML risk
April 09 2009
Genentech and FDA announced the withdrawal of psoriasis treatment Raptiva due to a risk of progressive multifocal leukoencephalopathy (PML), a ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.